| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Submission example | TARA-002 Lymphatic Malformations (LMs) | BLA | — | Cell Therapies | Rare Diseases | ||
BLA Submission example | TARA-002 Lymphatic Malformations (LMs) | BLA | — | Cell Therapies | Rare Diseases | ||
BLA Submission example | TARA-002 Lymphatic Malformations (LMs) | BLA | — | Cell Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Protara Therapeutics, Inc.$4.04
+0.22 (+5.76%)
C 44Pipeline Score Fair Value Biotech · Clinical
Market Cap
276.52 M
EPS
-1.35
P/E Ratio
-
Value Trade
2.20 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
13.56 M
Operating CF
-21.34 M
Total Assets
191.92 M
Total Liabilities
10.71 M
Equity
181.21 M
D/E Ratio
12,345
-4.09 %
Week
-7.52 %
1 Month
-30.51 %
3 Month
-23.96 %
6 Month
-48.16 %
5 Year
-98.91 %
All Time
Cash Data
Cash Position
135.79 M
Monthly Burn
7.11 M
Runway
17.7 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
1.39 M
52 Week Range
2.77 - 7.82
% held by Insiders
9.95 %
% held by Institutions
73.85 %
Enterprise Value
143.80 M
Total Shares
51.64 M
Short %
8.82 %
Float Shares
45.86 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Protara Therapeutics, Inc.
271Total events
3Upcoming
48Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 3
Event history 268
Q3 2026
◆Trial InitiationTARA-002Trial
Initiation of ADVANCED-3 registrational trial
BCG-Naïve and BCG-Exposed NMIBCsource ↗
Q3 2026
◆Enrollment CompleteTARA-002Trial
Expects to complete enrollment of BCG-Unresponsive registrational cohort of ADVANCED-2 trial in 2H 2026
non-muscle invasive bladder cancer (NMIBC)source ↗
Q3 2026
◆Interim AnalysisTrial
Interim results from THRIVE-3 registrational trial expected in 2H 2026
patients dependent on long-term parenteral supportsource ↗
May 26, 2026
◆Oral PresentationPresentation
Protara management to present at TD Cowen 7th Annual Oncology Innovation Summit
May 20, 2026
◆Poster PresentationTARA-002Presentation
Interim safety and durability data from STARBORN-1 at ISSVA 2026
Lymphatic Malformationssource ↗
May 19, 2026
May 19, 2026
◆Oral PresentationTARA-002Presentation
Virtual investor webinar on TARA-002 in LMs with KOL
Lymphatic Malformationssource ↗
May 15, 2026
◆Poster PresentationTARA-002Presentation
Encore poster presentation of previously reported data from Cohort B of ADVANCED-2 trial at AUA 2026
BCG-Unresponsive non-muscle invasive bladder cancersource ↗
May 15, 2026
▲Enrollment CompleteTARA-002Trial
Enrollment completed in BCG-Naïve cohort of ADVANCED-2
BCG-Naïve NMIBCsource ↗
Q2 2026
◆Enrollment CompleteTARA-002Trial
Enrollment completion expected in BCG-Unresponsive cohort of ADVANCED-2
BCG-Unresponsive NMIBCsource ↗
Q2 2026
◆Enrollment MilestoneTARA-002Trial
Expects to complete enrollment of BCG-Unresponsive registrational cohort in 2H 2026
Non-Muscle Invasive Bladder Cancer (NMIBC)source ↗
Drug Pipeline Intelligence
C44
Pipeline Score $414M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.5x
rNPV / MCap Top 65%
Micro Cap (rank 318 of 905)
Percentile RankProtara Therapeutics, Inc. carries a moderate pipeline score (44/100), with $2.5B risk-adjusted pipeline value, led by TARA-002 in Bladder (Urothelial, Transitional Cell) Cancer (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TARA-002 Small molecule | Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 | NCT07480356 | 90% | $2.1B | RECRUITING | 284 | VERY_FAST | C (50) | Nov 1, 2032 | LOW_RISK | LOW Jun 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TARA-002 | BCG-unresponsive non-muscle invasive bladder cancer | Phase 2 | 2026-02-24 | |||
TARA-002 | BCG-unresponsive non-muscle invasive bladder cancer | Phase 2 | 2026-02-24 | |||
TARA-002 | BCG-unresponsive non-muscle invasive bladder cancer | Phase 2 | 2026-02-24 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TARA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Protara Therapeutics, Inc. (TARA) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
TARA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TARA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TARA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TARA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
TARA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TARAProtara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Protara Therapeutics will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026. The event will provide insights related to ASCO and EHA. Protara is focused on developing therapies for cancer and rare diseases, including its lead candidate TARA-002, which is in Phase 2 trials.
Read more →TARAProtara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
Protara Therapeutics, Inc. will host a virtual webinar on May 19, 2026, to discuss its investigational therapy TARA-002 for Lymphatic Malformations. The event will cover the treatment landscape, expert opinions, and clinical data supporting TARA-002's use. TARA-002, which has received several FDA designations, is a first-in-class therapy aimed at enhancing immune response through the activation of critical immune pathways. Lymphatic Malformations are rare conditions that currently lack approved treatments.
Read more →TARAProtara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
Protara Therapeutics has announced positive 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC). The treatment demonstrated a 72% complete response rate at any time and a favorable safety profile. The company plans to initiate the ADVANCED-3 trial in the second half of 2026, further evaluating TARA-002's efficacy.
Read more →TARAProtara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Protara Therapeutics announced its Q1 2026 financial results and provided updates on its clinical programs. The company plans to submit a Biologics License Application for TARA-002 in Lymphatic Malformations by the second half of 2027. Protara also aims to complete enrollment in the ADVANCED-2 trial and initiate the ADVANCED-3 trial for non-muscle invasive bladder cancer in 2H 2026. The company reported a net loss of $17.8 million for the quarter but maintains strong cash reserves.
Read more →TARAProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
Protara Therapeutics announced that updated interim data from the Phase 2 ADVANCED-2 trial of TARA-002 will be presented at the AUA 2026 Annual Meeting. The trial evaluates TARA-002 in BCG-Naïve NMIBC patients, with data from 31 enrolled patients as of April 5, 2026. The presentation will include both safety and efficacy data.
Read more →TARAProtara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demons
Protara Therapeutics has announced its fourth quarter and full year 2025 financial results alongside positive interim data from the ADVANCED-2 trial for its lead candidate, TARA-002, in non-muscle invasive bladder cancer (NMIBC). The drug achieved a 68% complete response rate at six months in patients unresponsive to previous treatment. Additionally, the company anticipates completing enrollment for its registrational cohort in 2026, along with plans for a new trial. Protara is well funded, with $198 million available to continue its developmental program into 2028.
Read more →TARATARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Protara Therapeutics announced promising interim results from the Phase 2 ADVANCED-2 trial of TARA-002 for treating BCG-unresponsive non-muscle invasive bladder cancer. The therapy achieved a 68% complete response rate at six months, with no severe adverse events reported. The company plans to complete enrollment for the trial's BCG-unresponsive cohort by the second half of 2026.
Read more →TARAProtara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA) announced its participation in upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. At these conferences, management will engage in fireside chats to discuss the company's initiatives and progress. Protara is dedicated to developing innovative therapies for cancer and rare diseases, with TARA-002 currently in Phase 2 trials for non-muscle invasive bladder cancer and lymphatic malformations.
Read more →TARAProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2026
Protara Therapeutics, Inc. has announced the grant of inducement stock options and restricted stock units to a newly-hired employee. The grants include 10,200 stock options and 5,100 RSUs, with vesting schedules tied to the employee's continued service. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent as it develops therapies for cancer and rare diseases.
Read more →TARAProtara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
Protara Therapeutics announced that updated interim data from the Phase 2 ADVANCED-2 trial of TARA-002 will be presented at the ASCO Genitourinary Cancers Symposium. The trial focuses on BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients. The poster will detail safety and efficacy data from about 25 evaluable patients. TARA-002 is an investigational therapy that has shown potential in treating NMIBC.
Read more →TARAProtara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
Protara Therapeutics has announced significant updates and milestones for 2026, focusing on its investigational therapies for cancer and rare diseases. The company plans to report interim results for its ADVANCED-2 trial and has received FDA designations for TARA-002 in lymphatic malformations. In addition, Protara has dosed the first patient in the THRIVE-3 trial evaluating IV Choline Chloride, aiming to assist patients on parenteral nutrition. A recent public offering has further solidified the company's financial position, extending its cash runway into 2028.
Read more →TARAProtara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Protara Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is focused on developing therapies for cancer and rare diseases, including its lead candidate TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations. A live webcast of the presentation will be available on their website.
Read more →TARAProtara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
Protara Therapeutics has commenced patient dosing in its Phase 3 THRIVE-3 trial, evaluating IV Choline Chloride for patients on long-term parenteral support. This investigational therapy aims to address choline deficiency, which affects a significant percentage of this patient population. The trial follows an earlier Phase 2b study and aims to provide interim results in late 2026.
Read more →TARAProtara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
Protara Therapeutics announced that the FDA has granted Breakthrough Therapy and Fast Track designations for TARA-002, an investigational therapy for pediatric patients with lymphatic malformations. This recognition highlights the urgent need for effective treatments in this area. Additionally, TARA-002 has been selected for the CMC Development and Readiness Pilot Program, facilitating its development process.
Read more →TARAProtara Announces Closing of $75 Million Public Offering
Protara Therapeutics, Inc. has concluded a public offering of 13,043,479 shares at a price of $5.75 per share, raising approximately $75 million. The proceeds will be utilized primarily for the clinical development of TARA-002 and several other clinical programs. Additionally, the company has given underwriters a 30-day option to purchase up to 1,956,521 additional shares. This offering was part of an effective shelf registration statement and demonstrates strong interest from investors.
Read more →TARAProtara Announces Pricing of $75 Million Public Offering
Protara Therapeutics has announced the pricing of a public offering of 13,043,479 shares at $5.75 each, aiming to raise approximately $75 million. The offering is expected to close on December 8, 2025, and the funds will support the clinical development of TARA-002 and other programs. The company has granted underwriters a 30-day option to purchase additional shares.
Read more →TARAProtara Announces Proposed Public Offering
Protara Therapeutics, Inc. announced a proposed public offering to raise $75 million in aggregate through shares of its common stock and pre-funded warrants. The funds raised will primarily be directed towards the clinical development of TARA-002 and other clinical programs. The offering is contingent on market conditions, with potential adjustments to its size and terms. J.P. Morgan, TD Cowen, and Piper Sandler are managing the offering.
Read more →TARAProtara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Protara Therapeutics announced updated interim data from its Phase 2 ADVANCED-2 trial of TARA-002 for treating BCG-Naïve non-muscle invasive bladder cancer (NMIBC). The results indicate promising response rates and a favorable safety profile. The company is in discussions with the FDA regarding the regulatory pathway for TARA-002, aiming to expand its application to BCG-Naïve patients.
Read more →TARAInterim Data Presentation From the ADVANCED - 2 Trial of TARA - 002 in BCG - Na ve NMIBC Patients Society Of Urologic Oncology Annual Meeting December 2025 2 Statements contained in this presentation regarding matters th
The article discusses the interim data presentation from the ADVANCED - 2 trial involving TARA-002, which targets BCG-naive NMIBC patients. The presentation was made during the Society of Urologic Oncology Annual Meeting in December 2025. Key opinion leader Dr. Neal Shore contributed to the discussion, highlighting the potential implications of the results. This data presentation may influence future treatment options in this patient demographic.
Read more →TARAProtara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Protara Therapeutics announced positive interim results from its Phase 2 STARBORN-1 trial for TARA-002, a therapy for pediatric patients with lymphatic malformations. The trial showed that 7 out of 8 evaluable patients achieved clinical success, with a favorable safety profile. This therapy could provide a significant benefit to patients, as there are currently no approved treatments for lymphatic malformations.
Read more →TARASTARBORN - 1 Clinical Trial Interim Update
The article provides an interim update on the STARBORN - 1 clinical trial, focusing on TARA-002, which has shown significant results in treating patients with LMS. The data update reveals promising outcomes before and after treatment in two patients. This advance is highlighted by statements from company executives and involved researchers, indicating a hopeful outlook on TARA-002's efficacy.
Read more →TARAProtara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
Protara Therapeutics is set to host a conference call and webcast on November 19, 2025, to discuss new interim data from the Phase 2 STARBORN-1 trial of TARA-002 for pediatric patients with lymphatic malformations. TARA-002 is a cell-based therapy derived from a successful lineage used for similar conditions, having obtained Rare Pediatric Disease designation from the FDA. The conference aims to provide insights into the therapy's potential and the ongoing advancements in treating rare conditions in children.
Read more →TARAProtara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
Protara Therapeutics announced that interim data from the Phase 2 ADVANCED-2 trial of TARA-002 will be presented at the 26th Annual Meeting of the Society of Urologic Oncology. The trial focuses on BCG-Naïve patients with non-muscle invasive bladder cancer. The presentation will include updated safety and efficacy data from 31 enrolled patients.
Read more →TARAProtara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Protara Therapeutics reported its third quarter 2025 financial results, highlighting advancements in its clinical programs, particularly TARA-002 for non-muscle invasive bladder cancer (NMIBC). The company anticipates interim results from its ADVANCED-2 trial in early 2026 and is also progressing with its IV Choline Chloride and STARBORN-1 trials. CEO Jesse Shefferman emphasized the potential of TARA-002 to enhance NMIBC treatment options.
Read more →TARAProtara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
Protara Therapeutics has been named a BioSpace 2026 Best Place to Work, highlighting its commitment to a positive workplace culture. The company, recognized in the small employer category, values integrity, teamwork, and professional development. CEO Jesse Shefferman expressed gratitude towards employees for their dedication to advancing transformative therapies.
Read more →TARAProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. announced the grant of inducement stock options and RSUs to a newly-hired employee, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options total 6,200 shares with an exercise price of $4.41, while 3,100 RSUs were also granted. The vesting schedule for these awards is structured over four years for options and three years for RSUs, contingent on the employee's continued service.
Read more →TARAProtara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANC
Protara Therapeutics has reported its financial results for the second quarter of 2025 and outlined its ongoing clinical development efforts. The company is progressing with its ADVANCED-2 trial of TARA-002, targeting non-muscle invasive bladder cancer, with interim results anticipated in early 2026. Additionally, Protara plans to begin dosing patients in its THRIVE-3 trial for IV Choline Chloride by quarter's end and expects updates from the STARBORN-1 trial for pediatric lymphatic malformations later this year.
Read more →TARAProtara Therapeutics Announces Addition to the Russell 3000® Index
Protara Therapeutics has announced its inclusion in the Russell 3000 Index, effective June 30, 2025. This milestone reflects the company's advancements in clinical trials, particularly for its lead candidate TARA-002. The CEO emphasized the importance of this recognition for enhancing the company's visibility in the financial community. Protara continues to focus on developing therapies for cancer and rare diseases.
Read more →TARAProtara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
Protara Therapeutics has appointed William Conkling as Chief Commercial Officer, bringing over 20 years of experience in commercializing cancer and rare disease therapies. His previous roles include leadership positions at Rafael Holdings and Immunomedics, where he contributed to successful product launches. Conkling's expertise is expected to enhance Protara's transition into a commercial-stage organization.
Read more →TARAProtara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NM
Protara Therapeutics announced its first quarter 2025 financial results alongside a business update, highlighting positive interim results from its ADVANCED-2 trial for TARA-002 in treating non-muscle invasive bladder cancer (NMIBC). The interim results showcased durable 12-month responses in patients who were unresponsive or naïve to Bacillus Calmette-Guérin (BCG) therapy. Protara expressed confidence in TARA-002's potential to improve patient outcomes and is also making advancements in rare disease programs. The company anticipates several upcoming data milestones in the near future.
Read more →TARAProtara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC TARA-002 demonstrates 100% complete response rate at any
Protara Therapeutics announced interim results from its Phase 2 ADVANCED-2 trial of TARA-002, indicating a 100% complete response rate in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). The study showed durable responses and a favorable safety profile, with predominantly Grade 1 adverse events. The trial results are being presented at the American Urological Association 2025 Annual Meeting. Protara's continued focus is to advance TARA-002 as a transformative therapy for patients unresponsive to standard treatments.
Read more →TARAProtara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Protara Therapeutics announced promising interim results from its Phase 2 ADVANCED-2 trial for TARA-002, an investigational therapy for high-risk NMIBC patients. TARA-002 achieved a 100% complete response rate in BCG-Unresponsive patients and a 76% rate in BCG-Naive patients. The therapy displayed a favorable safety profile, with no severe treatment-related adverse events reported. Protara plans to provide further interim updates on patient responses by the end of 2025.
Read more →TARAProtara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
Protara Therapeutics has announced a conference call scheduled for April 28, 2025, to review interim safety and efficacy data from the Phase 2 ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC). The trial aims to provide information for BCG-unresponsive and naïve patients and is designed to align with FDA guidance for registration. Initial findings will also be presented at the American Urological Association's Annual Meeting on April 26, 2025. This trial is part of Protara's efforts to advance treatments for cancer and rare diseases.
Read more →TARAProtara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
Protara Therapeutics has appointed Dr. Leonardo Viana Nicacio as the new Chief Medical Officer. Dr. Nicacio brings nearly 20 years of experience in oncology and drug development, having held significant roles at several leading biopharmaceutical companies. His expertise is expected to guide Protara's ongoing efforts to advance therapeutic candidates for patients with underserved cancers and rare diseases. The company anticipates several important milestones, including interim data presentations for its investigational therapy, TARA-002, in the near future.
Read more →TARAProtara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
Protara Therapeutics has announced that it will present interim analysis data from the Phase 2 ADVANCED-2 trial of TARA-002 at the American Urological Association Annual Meeting. The trial focuses on treating patients with non-muscle invasive bladder cancer (NMIBC) who are either BCG-unresponsive or BCG-naïve. Presentations will include updated safety and efficacy results and will take place from April 26 to April 29, 2025. TARA-002 has shown promise as an investigational cell therapy in this patient population.
Read more →TARAProtara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
Protara Therapeutics announced that results from its THRIVE-1 study, which evaluates choline deficiency in patients reliant on parenteral support, will be presented at the ASPEN 2025 Conference. The study found that 78% of these patients are choline deficient, with a notable percentage experiencing liver dysfunction. Protara plans to begin the THRIVE-3 registrational trial for IV Choline Chloride in the first half of 2025, aiming to provide a critical source of choline for this patient group. The findings highlight a significant need for choline replacement therapy in the parenteral nutrition community.
Read more →TARAProtara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of
Protara Therapeutics announced its financial results for Q4 and full year 2024 alongside a business update. The company highlighted positive data from its ADVANCED-2 trial for TARA-002, a cell-based therapy targeting non-muscle invasive bladder cancer (NMIBC). With plans to report additional data from trials and commence a pivotal study for another product, Protara aims to advance its therapeutic offerings. The company also noted robust financial health, with operations funded through 2027.
Read more →TARAProtara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Protara Therapeutics, Inc. will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 5, 2025. The event highlights the company's ongoing commitment to developing therapies for cancer and rare diseases. Protara is currently evaluating its lead candidate, TARA-002, in clinical trials for non-muscle invasive bladder cancer and lymphatic malformations. This presentation allows stakeholders to gain insights into the company's strategic direction and research advancements.
Read more →TARAProtara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Protara Therapeutics, Inc. will participate in a virtual fireside chat during the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025. The company is known for developing therapies for cancer and rare diseases, including their lead candidate, TARA-002. Currently, TARA-002 is undergoing Phase 2 trials for treating non-muscle invasive bladder cancer and pediatric lymphatic malformations. Interested individuals can access the live webcast through Protara's website.
Read more →TARACORPORATE PRESENTATION January 2025 FORWARD LOOKING STATEMENTS 2 2025 Protara Therapeutics. All Rights Reserved - Do Not Copy or Distribute Statements contained in this presentation regarding matters that are not histori
Protara Therapeutics has released a corporate presentation detailing future strategies and product developments, including TARA-002 for conditions like non-muscle invasive bladder cancer and lymphatic malformations. The document outlines the company's focus on innovating therapies that cater to specific medical needs, including a phospholipid substrate replacement therapy for patients reliant on parenteral support. This presentation appears to set the stage for advancements in their therapeutic pipeline for 2025.
Read more →TARAProtara Highlights Recent Updates and Anticipated 2025 Milestones
Protara Therapeutics has announced significant updates and milestones for 2025, including positive results from the ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC). The company successfully completed a public offering, extending their financial runway into 2027. Key upcoming milestones include the reporting of further data from the ADVANCED-2 trial and the initiation of the pivotal THRIVE-3 study of intravenous Choline Chloride. The company aims to provide innovative treatments for cancer and rare diseases.
Read more →TARAProtara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Protara Therapeutics, Inc. announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 16, 2025. The conference presentation will focus on the company's innovative therapies for cancer and rare diseases. Protara's lead candidate, TARA-002, is currently in Phase 2 trials for non-muscle invasive bladder cancer and lymphatic malformations. The event will be accessible via a live webcast and will be archived for later viewing.
Read more →TARAProtara Announces Closing of $100 Million Public Offering
Protara Therapeutics, Inc. announced the successful closing of its underwritten public offering of approximately 13.7 million shares of common stock, generating around $100 million in gross proceeds. The offering's proceeds are intended for funding the clinical development of the company's TARA-002 therapy and other clinical programs. Furthermore, Protara has granted underwriters a 30-day option to purchase additional shares, which can further enhance funding. The offering occurred under an effective shelf registration statement with the U.S. Securities and Exchange Commission.
Read more →TARAProtara Announces Pricing of $100 Million Public Offering
Protara Therapeutics, Inc. has announced the pricing of its $100 million public offering of 13,690,000 shares of common stock at $6.25 per share, alongside pre-funded warrants. This transaction, expected to close on December 11, 2024, aims to fund the clinical development of its lead product, TARA-002, among other clinical programs. The offering will be managed by TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., and Scotiabank. The finances raised shall also serve for general corporate purposes.
Read more →TARAProtara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Protara Therapeutics announced encouraging results from its Phase 2 ADVANCED-2 trial evaluating TARA-002 in Non-Muscle Invasive Bladder Cancer (NMIBC) patients. The data show a 72% complete response rate at six months across various Bacillus Calmette-Guérin (BCG) exposures, with particularly high rates in BCG-Unresponsive patients. The safety profile was favorable, with no significant treatment-related adverse events reported. The company plans to accelerate patient enrollment and report additional data in mid-2025.
Read more →TARAADVANCED - 2 TRIAL INTERIM RESULTS December 2024 FORWARD LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of
ADVANCED - 2 TRIAL INTERIM RESULTS December 2024 FORWARD LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Prot
Read more →TARAProtara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
Protara Therapeutics, Inc. announced a conference call and webcast scheduled for December 5, 2024, to discuss interim data from the Phase 2 ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) patients. The data will also be presented during a poster session at the Society of Urologic Oncology's annual meeting on the same day. TARA-002, an investigational cell therapy, aims to treat patients who are unresponsive or naïve to standard BCG therapy, and has received Rare Pediatric Disease Designation from the FDA. This is part of Protara's commitment to developing transformative therapies for cancer and rare diseases.
Read more →TARAProtara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
Protara Therapeutics has announced that new interim data from its Phase 2 ADVANCED-2 trial of TARA-002 will be presented at the upcoming Society of Urologic Oncology meeting. This trial focuses on the use of TARA-002 for patients with non-muscle invasive bladder cancer (NMIBC), particularly those unresponsive to prior treatment. The data will include updated safety and efficacy results from around 20 enrolled patients. The trial is significant as it aligns with the FDA's guidance for the treatment of BCG-unresponsive NMIBC.
Read more →TARAProtara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024 Expec
Protara Therapeutics, a clinical-stage biotechnology firm, announced its financial results for Q3 2024 and outlined progress in its drug development programs. The company is set to report interim data from its ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer by the end of 2024. Additionally, Protara plans to start the pivotal THRIVE-3 study for intravenous Choline Chloride in early 2025, having received FDA Fast Track designation. TARA-002 is also under evaluation for lymphatic malformations, a rare pediatric condition, with interim data expected in 2025.
Read more →TARAProtara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Protara Therapeutics, a clinical-stage biotechnology company focused on cancer and rare diseases, will participate in the Guggenheim Inaugural Healthcare Innovation Conference on November 13, 2024. The event will include a fireside chat featuring the company's management. Protara is currently advancing its lead candidate, TARA-002, through Phase 2 trials. The webcast of the event will be available on the company's website after the live presentation.
Read more →TARAProtara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
Protara Therapeutics received FDA Fast Track designation for its investigational IV Choline Chloride, aimed at addressing choline deficiencies in patients on parenteral support. This designation emphasizes the urgent medical need for such therapy, as currently, no approved IV choline products exist for these patients. The company plans to initiate its registrational THRIVE-3 clinical trial in the first quarter of 2025, with expectations to evaluate the safety and efficacy of the treatment. Approximately 80% of patients receiving parenteral support may experience choline deficiency, which can lead to serious health complications.
Read more →TARAProtara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
Protara Therapeutics announced the results of its THRIVE-1 study, revealing that 78% of patients dependent on parenteral support suffer from choline deficiency, with 63% showing liver dysfunction. The findings emphasize the urgent need for intravenous choline supplementation, which the company is developing as IV Choline Chloride. Protara expects to commence a pivotal trial for this product in Q1 2025, potentially addressing a significant gap in treatment for these patients. The research was presented at the ESPEN Congress in Milan, further underscoring its relevance to clinical practice.
Read more →TARAProtara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Protara Therapeutics has completed the first cohort of the Phase 2 STARBORN-1 trial assessing TARA-002 for lymphatic malformations in pediatric patients. The trial has shown promising results, with two of three patients achieving a complete response to the investigational treatment. Following positive outcomes in this initial group, the company is proceeding with enrollment for additional cohorts, expecting to release more data in the first half of 2025. TARA-002, derived from the previously approved OK-432, is aimed at providing an effective therapeutic option for this rare pediatric condition.
Read more →TARAProtara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Protara Therapeutics, a clinical-stage biotechnology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024. During this event, the company will present insights regarding its clinical advancements, particularly focusing on TARA-002, its leading investigational therapy. Protara is currently evaluating TARA-002 in ongoing Phase 2 trials for non-muscle invasive bladder cancer and lymphatic malformations. The event reflects the company's efforts to engage with investors and stakeholders regarding its developmental pipeline.
Read more →TARAProtara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 202
Protara Therapeutics announced its financial results for Q2 2024 along with significant business updates. The company reported positive three-month data from its TARA-002 program for non-muscle invasive bladder cancer (NMIBC) and is set to provide interim data from its ADVANCED-2 trial in Q4 2024. Additionally, Protara has reached alignment with the FDA for its intravenous Choline Chloride product, which aims to address choline deficiency in patients on parenteral nutrition. The company continues to progress in its efforts to provide transformative therapies for cancer and rare diseases.
Read more →TARAProtara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. has announced the grant of 118,400 stock options to Lisa Schlesinger, its new Vice President, Head of New Product Development and Market Access, as part of her inducement package. The stock options have an exercise price of $2.23 each and will vest over a four-year period. This grant was approved by the independent members of Protara's Board of Directors, aligning with NASDAQ Listing Rule 5635(c)(4). Protara continues its focus on developing therapies for cancer and rare diseases, highlighted by its lead candidate, TARA-002.
Read more →TARAProtara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
Protara Therapeutics, Inc. will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024. The company is focused on developing transformative therapies for cancer and rare diseases, including its lead candidate TARA-002, which is currently in Phase 2 trials for treating non-muscle invasive bladder cancer and lymphatic malformations. A live webcast of the event will be available, along with an archived version for later viewing.
Read more →TARAProtara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Pr
Protara Therapeutics announced its financial results for Q1 2024 and provided a business update highlighting advancements in its clinical programs. The company reported positive data regarding TARA-002 for non-muscle invasive bladder cancer (NMIBC), and plans to present interim results from the ADVANCED-2 trial later this year. Additionally, Protara has aligned with the FDA on the development of intravenous Choline Chloride for patients reliant on parenteral nutrition. The firm continues to progress with its trials for TARA-002 in pediatric patients with lymphatic malformations.
Read more →TARAProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Protara Therapeutics announced encouraging results from the ongoing NMIBC program involving TARA-002, revealing a complete response rate of 43% in BCG-Unresponsive/Experienced patients and 63% in CIS-only patients after three months. The therapy demonstrated a favorable safety profile, with no serious adverse events reported. Preliminary results from a six-month evaluation in the ADVANCED-2 trial are anticipated in the second half of 2024. Experts express optimism that TARA-002 could enhance treatment options for patients with this challenging form of bladder cancer.
Read more →TARAProtara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Protara Therapeutics has announced a successful oversubscribed private placement financing, raising approximately $45 million through the sale of shares and warrants. The financing, supported by various institutional investors, is expected to close on April 10, 2024, and will help fund the company’s ongoing operations and clinical trials into 2026. Protara intends to use the proceeds mainly for general corporate purposes, including funding the ADVANCED-2 Phase 2 clinical trial of its product candidate TARA-002 in non-muscle invasive bladder cancer patients.
Read more →TARAProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition New development pathway significantly expands addressable patient pop
Protara Therapeutics has announced a significant milestone, reaching alignment with the FDA on a regulatory pathway for its investigational therapy, IV Choline Chloride, aimed at patients dependent on parenteral nutrition. This decision expands the development to a broader indication, reflecting the urgent need for effective choline supplementation in this patient population. With the FDA granting Orphan Drug Designation, Protara plans to initiate a clinical study to assess the safety and efficacy of the therapy. The company's efforts may lead to the first FDA approved IV choline therapy, providing hope for patients facing choline deficiency.
Read more →TARAProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H
Protara Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting a promising outlook for 2024. The company anticipates sharing Phase 1b proof of concept and preliminary Phase 2 data for TARA-002, its lead therapy for non-muscle invasive bladder cancer (NMIBC), later this year. Additionally, Protara is advancing its TARA-002 program for lymphatic malformations, indicating progress in treating underserved pediatric populations. While the company is optimistic about its pipeline, it also reported a decline in total current assets and acknowledged potential risks and uncertainties related to its financial guidance.
Read more →TARAProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Protara Therapeutics, Inc. announced its participation in the TD Cowen 44th Annual Health Care Conference scheduled for March 6, 2024. The company, focusing on innovative therapies for cancer and rare diseases, is set to engage in a fireside chat during the event. Protara is advancing its lead candidate TARA-002 in clinical trials for non-muscle invasive bladder cancer and lymphatic malformations. The webcast of the chat will be available on the company's website for those interested in following the presentation.
Read more →TARAProtara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
Protara Therapeutics has announced encouraging results from the Phase 1a ADVANCED-1 clinical trial of TARA-002 for high-grade non-muscle invasive bladder cancer. In this trial, five out of six patients with high-grade tumors showed high-grade recurrence-free survival at Week 12. The therapy was well tolerated, with no dose limiting toxicities reported. Protara expects to share preliminary results from the trial's expansion portion in the first half of 2024.
Read more →TARAProtara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H
Protara Therapeutics reported its financial results for Q3 2023 and provided a business update regarding its ongoing clinical trials. The company is currently dosing patients in the ADVANCED-2 trial focusing on non-muscle invasive bladder cancer and has plans to release preliminary results from the ADVANCED-1 trial in early 2024. Protara remains well-capitalized with a cash runway that extends into the second quarter of 2025, enabling it to pursue significant milestones in its TARA-002 programs.
Read more →TARAProtara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Protara Therapeutics has initiated dosing in the Phase 2 STARBORN-1 trial for TARA-002, a cell-based immunopotentiator aimed at treating pediatric patients with lymphatic malformations. The trial, which includes approximately 30 participants aged six months to less than 18 years, seeks to evaluate TARA-002's efficacy and safety through intracystic injection. This therapy addresses a significant unmet medical need, as no FDA-approved treatments currently exist for this rare condition. TARA-002 has received Rare Pediatric Disease designation, and its potential benefits are backed by previous observations with its predecessor, OK-432.
Read more →TARAProtara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
Protara Therapeutics has announced the initiation of dosing for the first patient in its Phase 1b/2 ADVANCED-2 trial, which is evaluating TARA-002 for patients with high-grade non-muscle invasive bladder cancer (NMIBC). The trial aims to assess the efficacy of TARA-002 in both BCG-naïve and BCG-unresponsive populations. This development follows positive findings from the prior ADVANCED-1 trial, which indicated good tolerability and anti-tumor activity of the treatment. Protara is hopeful that TARA-002 could significantly impact the NMIBC treatment landscape.
Read more →TARAProtara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Protara Therapeutics, a clinical-stage biopharmaceutical company, announced their participation in the H.C. Wainwright 25th Annual Global Investment Conference scheduled for September 11, 2023, at 9:30 am ET in New York. The presentation will highlight Protara's commitment to advancing innovative therapies for cancer and rare diseases, including its lead programs. A live webcast of the presentation will be available on their website, along with an archived version afterward.
Read more →TARAProtara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update Dosing is progressing on schedule in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expect
Protara Therapeutics, Inc. reported its second quarter 2023 financial results and provided updates on its business activities. The company highlighted the ongoing dosing in the ADVANCED-1 trial for TARA-002, an investigational therapy for non-muscle invasive bladder cancer (NMIBC), with preliminary results anticipated in the first half of 2024. Additionally, Protara aims to initiate two more trials for TARA-002 later this year while maintaining a disciplined investment strategy, citing a strong financial position with sufficient cash projected through 2025.
Read more →TARAProtara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
Protara Therapeutics has dosed the first patients in the Phase 1b ADVANCED-1EXP trial for TARA-002, an investigational therapy aimed at treating high-grade non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS). This follows positive preliminary data from the Phase 1a segment of the trial, indicating TARA-002's potential in a space with limited treatment options. The trial aims to evaluate the safety, tolerability, and signs of anti-tumor activity in its participants. Further development includes a planned Phase 1b/2 trial targeting BCG-unresponsive CIS patients, expected to enroll 102 individuals in total.
Read more →TARAProtara Therapeutics Announces First Quarter 2023 Financial Results and Business Update Favorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trial Company plans to
Protara Therapeutics recently released its financial results for Q1 2023 and provided updates on its clinical programs. The company reported positive preliminary data for TARA-002, which is currently being tested in high-grade non-muscle invasive bladder cancer. In addition to this, Protara plans to initiate the Phase 1b/2 ADVANCED-2 trial and has received FDA clearance for another trial related to lymphatic malformations. The company aims to progress its innovative therapies to meet the needs of patients with limited treatment options.
Read more →TARAProtara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations STARBORN-1 trial leverages data from TARA-002 predecessor th
Protara Therapeutics has announced that it received regulatory clearance from the FDA to initiate the Phase 2 STARBORN-1 trial of TARA-002, aimed at treating pediatric patients with lymphatic malformations. This investigational therapy, based on the prior treatment OK-432, has shown promise in earlier studies and addresses a significant unmet medical need, as no approved treatments currently exist for the condition. The trial is set to commence in the fourth quarter of 2023, enrolling approximately 30 young patients.
Read more →TARAProtara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development Favorable tolerability observed in pat
Protara Therapeutics announced positive preliminary data from its ADVANCED-1 Phase 1a trial for TARA-002, a cell-based therapy targeting high-grade non-muscle invasive bladder cancer (NMIBC). The results show favorable tolerability and initial evidence of anti-tumor activity, prompting the company to advance the therapy into larger trials to assess TARA-002's effectiveness further. Protara plans to initiate the ADVANCED-2 trial later in 2023, involving BCG-naïve and BCG-unresponsive patients. The ongoing research underscores a potential breakthrough for patients with limited treatment options for NMIBC.
Read more →TARAProtara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladde
Protara Therapeutics announced its financial results for the fourth quarter and full year 2022, highlighting critical upcoming milestones for its lead product TARA-002. Data from the Phase 1a portion of the ADVANCED-1 trial treating non-muscle invasive bladder cancer is anticipated by the second quarter of 2023. Additionally, the start-up activities for the Phase 2 trial targeting lymphatic malformations are underway, with an initiation expected in the latter half of this year. Protara's cash position of $102.3 million is forecasted to support operations and data milestones through 2025.
Read more →TARAProtara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
Protara Therapeutics, Inc. has announced its participation in the Guggenheim Healthcare Talks Oncology Day, scheduled for February 9, 2023, at 11:20 am ET. The company will engage in a fireside chat during the event, which will also be accessible via a live webcast. Protara is a clinical-stage biopharmaceutical company dedicated to advancing therapies for cancer and rare diseases, including its lead program, TARA-002.
Read more →TARAProtara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
Protara Therapeutics has announced the appointment of Patrick Fabbio as Chief Financial Officer, effective January 30, 2023. Fabbio joins with over 30 years of experience in the life sciences and pharmaceutical industries, previously serving in key financial roles at several companies. This leadership change aims to support Protara's ongoing development of transformative therapies, particularly its lead product TARA-002, aimed at treating non-muscle invasive bladder cancer and lymphatic malformations. The company seeks to leverage Fabbio's expertise as it advances its pipeline and strategic goals.
Read more →TARACORPORATE PRESENTATION January 2023 FORWARD LOOKING STATEMENTS 2 2023 Protara Therapeutics. All Rights Reserved - Do Not Copy or Distribute Statements contained in this press release regarding matters that are not histor
Protara Therapeutics presented updates on its developmental product TARA-002, focusing on its applications for treating Non-Muscle Invasive Bladder Cancer and Lymphatic Malformations. The presentation also mentioned IV Choline Chloride's use in Intestinal Failure Associated Liver Disease. The details provided highlight ongoing developments in their therapeutic pipeline without specifying clinical outcomes or immediate market impacts.
Read more →TARAProtara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVAN
Read more →TARAProtara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview - Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Foll
Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview - Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Admin
Read more →TARAProtara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 24th Annual Glob
Read more →TARAProtara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview - Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - Strong
Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Strong Cash, Cash Equivalents and Investments Position of $112.8M as of June
Read more →TARAProtara Therapeutics Announces Departure of Chief Financial Officer New York
Protara Therapeutics Announces Departure of Chief Financial Officer New York, June 21, 2022 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that Blaine Da
Read more →TARAProtara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANC
Read more →TARAProtara Therapeutics to Present at the H.C. Wainwright Global Investment Conference
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright Global Investment
Read more →TARAProtara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the results of a retrospective analysis of OK-432, the originator comp
Read more →TARAProtara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview - Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Stro
Therapeutics Announces First Quarter 2022 Financial Results and Business Overview Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - Strong Cash, Cash Equivalents and Investments Position of $119M as of Marc
Read more →TARAProtara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer
NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has dosed the first patient in ADVANCED-1, its Phas
Read more →TARAProtara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview - Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position
Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview - Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021 Expected to Fund Ope
Read more →TARAProtara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Gu
Read more →TARAProtara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer
Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer YORK, January 10, 2022 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced th
Read more →TARAProtara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C.
Read more →TARAProtara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview - TARA-002 Confirmatory Large-Scale GMP Comparability Complete - - U.S. FDA Cleared the Company's IND Application for TARA-002 in
Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview TARA-002 Confirmatory Large-Scale GMP Comparability Complete - U.S. FDA Cleared the Company's IND Application for TARA-002 in NMIBC; Company Plans to Initiate Phase 1 Clinical Trial by Year-End S
Read more →TARAProtara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer -- Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End
Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End -- IND Application Included Submission of Confirmatory Large-Scale Compar
Read more →TARAProtara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Opp
Read more →TARAProtara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
-Study found that approximately 30% of patients who are dependent on parenteral nutrition have cholestasis- -Results support significant unmet medical need in patients dependent on parenteral nutrition who have intestinal failure associated liver disease- NEW YORK, Sept. 13, 20
Read more →TARAProtara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C
Read more →TARAProtara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview - Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End
Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview - Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End - - TARA-002 GMP Scale up and Comparability Ongoing an
Read more →TARAProtara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Lade
Read more →TARAProtara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors NEW YORK, June 10, 2021 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significa
Read more →TARAProtara Therapeutics to Participate in Upcoming Virtual Investor Conferences
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcom
Read more →TARAProtara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview
- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End - - On Track to Complete TARA-002 GMP Scale up and Comparability in 2H, 2021 - - Plan to Engage with FDA and Initiate Clinical Study of TARA-002 in Lymphatic Malformations - - Stro
Read more →TARAProtara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations Company to conduct additional clinical study to support submission of a Biologics License Application for TARA-002
Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations Company to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in Lymphatic Malformations NEW YORK, April 23, 2021 --
Read more →TARAProtara Therapeutics Announces Appointment of Mart n Sebastian Olivo, M.D. as Chief Medical Officer
Protara Therapeutics Announces Appointment of Mart n Sebastian Olivo, M.D. as Chief Medical Officer NEW YORK, April 19, 2021 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases
Read more →TARAProtara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview
- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End - - In Discussions with FDA on Next Steps Needed to File BLA for TARA-002 in Lymphatic Malformations - - On Track to Complete GMP Scale up and Comparab
Read more →TARAProtara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference
NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that members of the management team wil
Read more →TARACorporate Presentation February 2021 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" wi thi n the meaning of the Priva
Corporate Presentation February 2021 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" wi thi n the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, i
Read more →TARAProtara Therapeutics to Present at Upcoming Virtual Investor Conferences
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upco
Read more →TARAProtara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors NEW YORK, February 2, 2021 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significa
Read more →TARAProtara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the promotion of Jacqueline (Jackie) Zum
Read more →TARAProtara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview
- On Track to Complete GMP Batch Runs in Mid-2021 to Confirm Comparability Between TARA-002 and OK-432 - - Expect to Initiate Phase 1 Trial for TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer in 2021 - - Requested Meeting with FDA to Discuss Path Forward for TARA-0
Read more →TARAProtara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that its Chief Executive Officer, Jesse
Read more →TARAProtara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the pricing of two concurrent but separ
Read more →TARAProtara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare d
Read more →TARAProtara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications - Company Demonstrates Initial Comparability Between TARA-002 and OK-43
Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications - Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs - - Reaches
Read more →TARAProtara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. “W
Read more →TARAProtara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pe
Read more →TARAProtara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors
Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors NEW YORK, NY - July 24, 2020 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today
Read more →TARAProtara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Tra
Read more →TARAProtara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the first quarter ended March 31, 2020. “We re
Read more →TARAArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer
Therapeutics Appoints Blaine Davis as Chief Financial Officer NEW YORK, February 11, 2020 - ArTara Therapeutics, Inc. (Nasdaq: TARA) ("ArTara" or the "Company"), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with s
Read more →TARAArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics Shares of ArTara to commence trading on Nasdaq under new ticker symbol "TARA" effective
Therapeutics Completes Merger Transaction with Proteon Therapeutics of ArTara to commence trading on Nasdaq under new ticker symbol "TARA" effective January 10, 2020 completes previously announced equity financing of $42.5 million concurrently with the closing of the merger co
Read more →TARAArTara Therapeutics and Proteon Therapeutics Proposed Combination Webcast Tuesday, September 24 th 2019 ArTara and Proteon Proposed Merger Webcast Tuesday, September 24 th 2019 Cautionary Statement Regarding Forward-Look
ArTara Therapeutics and Proteon Therapeutics Proposed Combination Webcast Tuesday, September 24th 2019 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts are forward-lookin
Read more →TARAProteon Therapeutics and ArTara Therapeutics Agree to Combine Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing t
Proteon Therapeutics and ArTara Therapeutics Agree to Combine Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare Dedicated Investors
Read more →TARAProteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas - Investigational Vonapanitase Did Not Meet Co-Primary Endpoints - WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeuti
Read more →TARAProteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD
Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD - Trial Did Not Meet Primary Efficacy Endpoint - - Important Secondary and Tertiary Endpoint Data and Enrollment in Second Phase 3 Ongoing -
Read more →TARAProteon Therapeutics Appoints Scott Toner as Senior Vice President of Marketing
Proteon Therapeutics Appoints Scott Toner as Senior Vice President of Marketing WALTHAM, Mass., June 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney
Read more →TARAProteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease Patients Undergoing Surgical Creatio
Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease Patients Undergoing Surgical Creation of an Arteriovenous Fistula for Hemodialysis Data to be Presented at the National Kidney Foundati
Read more →Competitive Position
How TARA ranks across every disease it competes inCompetitive Position is a premium feature
See how TARA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial